Hi folks, wow...what a roller coaster ride it's been with RIMM--I tripled my gains from oct to just last week!!!
Anyways,apologies for being off ALXA--Back to ALXA
I had the oppty to actually be in the bay area this past month to meet up with fellow venture capitalists and fund friends,in the meantime I did have a chance to talk to some of my buddies there abt the bio pharms scene in general at the palo alto/SF area. This is wht I have to say based on my experience and connections and please please do not take this as investment advise or any other kind of manipulative talk.Thats my disclosure firstly! :-)
Ok now that we have estd. tht, let me say this 2013 LOOKS TO BE ONE OF THE BIGGEST YEARS AS FAR AS M&A is concerned. cash coffers are up at least 32% in this part of the world and many are looking for pharma/bio to invest in/merge with,so that the first good sign.
Alexza has been quiet for sometime now,not because of lack of news or progress but because they are now prepping for Europe approval,many people underestimate the market in Europe,but feb is what ALXA management is marching towards--Groupo is already developed a sales pipeline for this drug btw (don't ask me how I know this) in Europe and from what I can say it is in upwards of $25M in 2013 alone knowing pretty well tht the actual manufacturing of this system is going to happen in July/august timeframe,thats a total of $50M for a Full Year assessment--which is great! and just in Europe!!! even better.
Alxa has also btw been actively looking for partners in the USA,thats the word on the street and inner circles, due deligince is on the progress for the right marketing channel, which is even better i.e they are taking their jobs seriously and partnering with the right candidates. I won't be surprised of a partner announcement by the end of 1Q'13 if my sources are hinting towards the rgt step.
I STILL HAVE ALL MY SHARES IN THIS so don't worry I'm with you and will stick by this company for th elong run. Always remember investing SHOULD NOT be a 1-2 month strategy, it is a 1-2 YEAR strategy,so for everyone who is trying to make a quick buck on this at the flip of a switch--STAY AWAY FROM TRADING especially biotech. For those who want to grow their investments with this,I am very very sure they will reap benefits in the near future or so.
Hope that helps folks.
Sentiment: Strong Buy
Thank you for your note. We will be updating investors when there is material information to provide to shareholders. The company is in active discussions with commercial partners for the US market, and anticipate making an announcement on Alexza’s commercial strategy by the end of Q1 2013, if not sooner. Once Alexza has finalized its commercial strategy, we plan to hold a conference call to update all investors on the strategy.
Alexza also remains firmly on track for a Q3 launch of ADASUVE in the US and in Europe.
At the end of the day, biotechnology companies are longer-term focused investments. ADASUVE is a best-in-class, novel new therapeutic that we believe will fundamentally change the way medicine is practiced in the field of psychiatry. We anticipate that the long-term success of ADASUVE will drive shareholder value. You can expect to hear from Alexza when we have a significant update for our shareholders. Thank you again for your interest.
Sentiment: Strong Buy
$50M for this year alone in Europe that brings to PE ration x4 =$ 200m
and in the USA? let say $100M that brings to PE ration x4 =$400m
that is total $600m / 16m OS =$37 per share, we must be trading around these levels by 1Q of this yr when we get EU approval and a partner announcement.
Guys this stock was trading at $ 40 + last year on the hope of approval at a time when it was doubtful. Now that it's approved and with visible potential it is fair to say that it's way way undervalued at this current levels. So to the manipulators wherever that may be I say thanks for such a good bargain price (: